Abstract 1961P
Background
Sarcomas are rare malignant tumors and represent a heterogeneous group of tumors. An accurate diagnosis of histology is important for treatment strategies. We assessed the pathological review of all patients diagnosed with sarcoma at Siriraj Hospital over a 5-year period to identify the number of first diagnoses compared to the central expert review.
Methods
Histological data from patients diagnosed with sarcoma at Siriraj Hospital were collected over a 5-year period. The initial diagnoses were compared with a certified soft tissue and bone tumor pathologist.
Results
Of the 185 selected patients, 107 (57%) met the inclusion criteria and were analyzed. Full concordance between primary diagnosis and second opinion (the first pathologist and expert reached identical conclusions) was observed in 35 (32.7%) cases, partial concordance (identical diagnosis of connective tumor but different grade or histological type) in 12 (11.2%) cases, and complete discordance (benign versus malignant, different histological type, or invalidation of the diagnosis of sarcoma) in 60 (56.1%) cases. The rate of discordance was higher in incomplete initial IHC (p = 0.003), private laboratory, grade 2 and 3, tumor size ≥ 100 mm (p = 0.01) and age >18. The most common 'full concordance' histology is osteosarcoma (100%, 4 of 4). The main discrepancies were related to histological type (n = 60, 56.1%), subtype (n = 8, 7.5%), and grade plus subtype (n = 4, 3.7%). The mean duration from diagnosis to treatment was 96 days. Only the complete initial report appeared different in the subgroup <97 days group 39 (73.6%) and 97 days group 14 (26.4%) (p=0.03).
Conclusions
More than 65% of the first histological diagnoses were modified in the second reading, possibly resulting in different treatment decisions. The second opinion of the expert improves the quality of diagnosis and possibly the treatment of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15